Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib tablet bioavailability study in healthy volunteers
NCT07214922Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evobrutinib (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity at 24 hours and Maximum Observed Plasma Concentration at 24 hours. Started Jan 2023; status: completed.
02
Drugs
evobrutinib
Beyond the preview
Go deeper on NCT07214922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214922.